

**AN INTEGRATIVE APPROACH TO TUBERCULOSIS MANAGEMENT: MODERN
THERAPEUTICS AND AYURVEDIC SUPPORT**

Amruta Mahadev Korake*, Suchita Jagdale, Sneha Vedpatak, Nita Sid, Prathibha R. Adnaik

Anandi Pharmacy College Kalambe Tarf Kale, Kolhapur.

***Corresponding Author: Amruta Mahadev Korake**

Anandi Pharmacy College Kalambe Tarf Kale, Kolhapur.

DOI: <https://doi.org/10.5281/zenodo.19883456>**How to cite this Article:** Amruta Mahadev Korake*, Suchita Jagdale, Sneha Vedpatak, Nita Sid, Prathibha R. Adnaik (2026). An Integrative Approach To Tuberculosis Management: Modern Therapeutics And Ayurvedic Support. European Journal of Pharmaceutical and Medical Research, 13(5), 41–43.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 26/03/2026

Article Revised on 15/04/2026

Article Published on 01/05/2026

ABSTRACT

Tuberculosis (TB) remains one of the most significant infectious diseases worldwide, posing a major public health challenge despite the availability of effective chemotherapeutic agents. Caused by *Mycobacterium tuberculosis*, TB primarily affects the lungs but may also involve extrapulmonary sites, leading to diverse clinical manifestations. Globally, millions of new cases are reported annually, with low- and middle-income countries, particularly India, bearing a disproportionate burden of the disease. The emergence of drug-resistant forms of TB further complicates disease management and threatens global control efforts. This article provides a comprehensive overview of tuberculosis, including its epidemiology, etiology, clinical features, diagnosis, treatment, and prevention, while also exploring the Ayurvedic conceptualization and adjunctive therapeutic approaches. Integration of evidence-based traditional therapies with standard anti-tubercular treatment may offer supportive benefits; however, modern chemotherapy remains the cornerstone of TB management. Continued research and integrative strategies are essential to strengthen TB control and move toward global elimination goals.

KEYWORDS: Ayurvedic conceptualization and adjunctive therapeutic approaches.**INTRODUCTION**

Tuberculosis (TB) is a chronic infectious disease caused by *Mycobacterium tuberculosis*, an acid-fast, aerobic bacillus that primarily affects the lungs but may also involve other organs such as lymph nodes, bones, kidneys, and the central nervous system. TB remains one of the leading causes of death from a single infectious agent globally, despite the availability of effective chemotherapy for several decades.^[1] The disease spreads through airborne droplets expelled when an infected individual coughs, sneezes, or speaks, making it highly transmissible in crowded and poorly ventilated environments.^[2]

Modern TB management relies on prolonged multidrug regimens under standardized treatment programs, supported by rapid molecular diagnostics and public health interventions. However, challenges such as treatment non-adherence, adverse drug reactions, malnutrition, and immunosuppression continue to affect therapeutic outcomes. In this context, traditional medical

systems such as Ayurveda offer complementary perspectives on TB management. In Ayurvedic literature, TB is correlated with *Rajayakshma*, a chronic wasting disorder characterized by tissue depletion, impaired digestion, and doshic imbalance. Ayurvedic management emphasizes *Rasayana* therapy, dietary regulation, and use of immunomodulatory herbs aimed at restoring strength and improving host resistance.

Global Burden and Epidemiology

According to the World Health Organization (WHO), an estimated **10.6 million people developed TB globally**, and approximately **1.3 million deaths** were reported in 2023, highlighting TB as a persistent public health challenge.^[1] Low- and middle-income countries bear the majority of the disease burden, with Asia and Africa accounting for more than 85% of total cases. Factors such as poverty, malnutrition, HIV co-infection, and limited access to healthcare significantly contribute to TB transmission and poor treatment outcomes.^[1,3]

Tuberculosis in India

India accounts for nearly **one-fourth of the global TB burden**, making it the highest TB-burden country worldwide.^[1] To address this challenge, the Government of India implemented the **National Tuberculosis Elimination Programme (NTEP)**, aiming to eliminate TB by 2025 through early diagnosis, free treatment, and patient-centric care.^[4] Molecular diagnostic tools such as CBNAAT and TrueNat have significantly improved early case detection and identification of drug resistance.^[5]

Etiology and Transmission

TB is caused by *Mycobacterium tuberculosis*, a slow-growing intracellular pathogen. Infection occurs primarily via inhalation of droplet nuclei containing the bacilli. Once inhaled, the bacteria reach the alveoli, where they are engulfed by macrophages and may either be eliminated or persist in a latent form.^[2] Reactivation of latent TB occurs when host immunity declines due to malnutrition, HIV infection, diabetes, or immunosuppressive therapy.^[3]

Types of Tuberculosis

- **Latent TB Infection (LTBI):** Asymptomatic and non-infectious state with potential for future reactivation.^[1]
- **Active TB Disease:** Symptomatic and infectious form requiring immediate treatment.
- **Pulmonary TB:** Affects the lungs and is the most common form.
- **Extrapulmonary TB:** Involves organs other than lungs.
- **Drug-Resistant TB:** Includes multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), posing major therapeutic challenges.^[6]

Clinical Manifestations

Common symptoms of active pulmonary TB include persistent cough lasting more than two weeks, hemoptysis, fever, night sweats, weight loss, fatigue, and chest pain.^[2] Extrapulmonary TB presents with organ-specific symptoms depending on the site involved, such as lymphadenopathy, bone pain, or neurological manifestations.^[7]

Diagnosis

Diagnosis of TB involves a combination of clinical, radiological, and microbiological investigations. Sputum smear microscopy, chest X-ray, culture techniques, and nucleic acid amplification tests (NAATs) such as GeneXpert and TrueNat are widely used for rapid and accurate diagnosis.^[5] Drug susceptibility testing is essential for detecting drug-resistant TB and guiding appropriate therapy.^[6]

Treatment and Management

Modern Medical Treatment

Drug-sensitive TB is treated using a **6-month multidrug regimen** consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol, administered under the

DOTS strategy to ensure adherence.^[4] Drug-resistant TB requires longer treatment with second-line drugs such as bedaquiline, linezolid, and fluoroquinolones, often extending up to 18–24 months.^[6]

Supportive Public Health Measures

Nutritional support schemes such as **Nikshay Poshan Yojana** provide financial assistance to TB patients in India to improve treatment outcomes and reduce mortality.^[8]

Prevention and Control

Preventive strategies include early case detection, complete treatment adherence, contact tracing, and vaccination with the **BCG vaccine**, which provides protection against severe forms of TB in children.^[1] Infection control measures such as improved ventilation and respiratory hygiene are crucial in high-risk settings.^[2]

Ayurvedic Perspective on Tuberculosis (Rajyakshma)

In Ayurveda, TB is correlated with **Rajyakshma**, a chronic wasting disease described in classical texts such as *Charaka Samhita*. Rajyakshma is characterized by progressive tissue depletion (*dhatu-kshaya*), impaired digestion (*agnimandya*), and imbalance of *Vata* and *Kapha doshas*.^[9]

Ayurvedic Pathogenesis and Management

Ayurvedic management emphasizes restoration of digestive fire, nourishment of depleted tissues, and enhancement of immunity through *Rasayana* therapy. Herbs such as **Ashwagandha** (*Withania somnifera*), **Guduchi** (*Tinospora cordifolia*), **Pippali** (*Piper longum*), and **Yashtimadhu** (*Glycyrrhiza glabra*) are traditionally used for respiratory and wasting disorders.^[10]

Evidence and Limitations

Several studies suggest that Ayurvedic formulations may serve as **adjunctive therapy** to modern anti-TB treatment by improving appetite, weight gain, and drug tolerance.^[11,12] However, Ayurvedic therapy should **not replace standard anti-tubercular drugs**, and integration must be evidence-based and supervised by healthcare professionals.

CONCLUSION

Tuberculosis remains a major global health concern due to its high transmission potential, association with socio-economic determinants, and increasing drug resistance. Effective control requires early diagnosis, strict adherence to multidrug therapy, and comprehensive public health interventions. Ayurvedic approaches may offer supportive benefits when used alongside modern medical treatment, but anti-tubercular chemotherapy remains the cornerstone of TB management. Continued research and integrated healthcare strategies are essential to achieve global TB elimination goals.

REFERENCES

1. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment and care. Geneva: World Health Organization, 2025.
2. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
3. National Institutes of Health. Treatment of tuberculosis: A review of guidelines. Bethesda: NCBI Bookshelf, 2019.
4. Samal J. Ayurvedic management of pulmonary tuberculosis: A systematic review. *J Intercult Ethnopharmacol*, 2015; 5(1): 86–91.
5. Debnath PK, Chattopadhyay J, Mitra A, Adhikari A, Alam MS, Bandopadhyay SK. Adjunct therapy of Ayurvedic medicine with anti-tubercular drugs on pulmonary tuberculosis. *J Ayurveda Integr Med*, 2012; 3(3): 141–9.
6. Sharma P, Goyal RK, Nandave M. Prevention, treatment and management of tuberculosis through combinational approaches of Indian systems of medicine. *J Complement Integr Med*, 2020; 17(2): 1–10.
7. Hyma P, et al. Ayurvedic approach towards the treatment for Mycobacterium tuberculosis. *Int Res J Ayurveda Yoga*, 2021; 4(6): 120–5.
8. Bala K, Goyal M. Ayurvedic approach in the management of pulmonary tuberculosis (Rajayakshma): A case report. *J Ayurveda Integr Med Sci*, 2025; 10(1): 45–9.
9. Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. *Lancet Infect Dis*, 2018; 18(7): e183–98.
10. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official ATS/CDC/IDSA clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis*, 2016; 63(7): e147–95.
11. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment and management—an update on treatment regimens, trials, and adjunct therapies. *Lancet Respir Med*, 2015; 3(3): 220–34.
12. Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. *Nat Rev Immunol*, 2015; 15(4): 255–63.
13. Parihar SP, Guler R, Khutlang R, Lang DM, Hurdal R, Mhlanga MM, et al. Statin therapy reduces the burden of tuberculosis in mice. *J Infect Dis*, 2014; 209(5): 754–63.
14. Singh RH. Exploring issues in the development of Ayurvedic research methodology. *J Ayurveda Integr Med*, 2010; 1(2): 91–5.
15. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. *Curr Sci*, 2004; 86(6): 789–99.
16. Dash B, Sharma BK. Charaka Samhita. Varanasi: Chowkhamba Sanskrit Series Office, 2014.
17. Murthy KRS. Sushruta Samhita. Varanasi: Chaukhamba Orientalia, 2012.
18. Government of India. National Tuberculosis Elimination Programme (NTEP) guidelines. New Delhi: Ministry of Health and Family Welfare, 2021.
19. Kaur R, Kaur J, Singh J. Immunomodulatory role of herbal drugs in tuberculosis. *Int J Pharm Sci Rev Res*, 2014; 26(2): 232–7.
20. Gupta R, Thakur B, Singh P, Singh HB, Sharma VD, Katoch VM, et al. Anti-tuberculosis activity of selected medicinal plants against multidrug-resistant Mycobacterium tuberculosis isolates. *Indian J Med Res*, 2010; 131: 809–13.